Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

9.210 +0.070 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolysse™ Recognized in 2025 Shape Skin Awards
From Evolus
Via Business Wire
Evolus Announces Departure of its Chief Financial Officer
From Evolus
Via Business Wire
Earnings Scheduled For May 7, 2025
Via Benzinga
Assessing Evolus: Insights From 6 Financial Analysts
Via Benzinga
Breaking Down Evolus: 4 Analysts Share Their Views
Via Benzinga
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
What Analysts Are Saying About Evolus Stock
Via Benzinga
4 Analysts Have This To Say About Evolus
Via Benzinga
Evolus Reports First Quarter 2025 Results
From Evolus
Via Business Wire
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
From Evolus
Via Business Wire
Evolus to Report First Quarter Financial Results on May 7, 2025
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Evolus Announces Commercial Launch of Evolysse™
From Evolus
Via Business Wire
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
Breaking Down Evolus: 8 Analysts Share Their Views
Via Benzinga
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
There's a lot going on for investors. 
Via The Motley Fool
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
From Evolus
Via Business Wire
Earnings Scheduled For March 4, 2025
Via Benzinga
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
From Evolus
Via Business Wire
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
From Evolus
Via Business Wire
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
From Evolus
Via Business Wire
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates
Via Benzinga
Crude Oil Down 2%; D.R. Horton Earnings Top Views
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.